{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:53:05Z","timestamp":1788457985362,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T00:00:00Z","timestamp":1412812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ctrv.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T00:36:25Z","timestamp":1410827785000},"page":"1230-1238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors"],"prefix":"10.1016","volume":"40","author":[{"given":"Juan W.","family":"Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-4732","authenticated-orcid":false,"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.09.001_b0005","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0010","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2014.09.001_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-4-29","article-title":"Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors","volume":"4","author":"Kulke","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0020","unstructured":"SUTENT\u00ae Summary of Product Characteristics. European Medicines Agency (http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000687\/human_med_001069.jsp) [accessed September 2, 2013]."},{"key":"10.1016\/j.ctrv.2014.09.001_b0025","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","article-title":"FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors","volume":"17","author":"Blumenthal","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2014.09.001_b0030","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0035","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.001_b0045","first-page":"1872","article-title":"Advances in pancreatic neuroendocrine tumor treatment","volume":"364","author":"Castellano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.001_b0050","unstructured":"SUTENT\u00ae Prescribing Information. Pfizer. <http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=607>; 2011 [accessed September 2, 2013]."},{"key":"10.1016\/j.ctrv.2014.09.001_b0055","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0060","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2014.09.001_b0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2014.09.001_b0075","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0080","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0090","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2014.09.001_b0095","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.09.001_b0100","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0105","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S0959-8049(11)70784-5","article-title":"Neutropenia and thrombocytopenia during treatment as bio markers of sunitinib efficacy in patients with metastatic renal cell carcinoma","volume":"47","author":"Donskov","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0110","first-page":"S135","article-title":"Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma","volume":"47","author":"Davis","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0115","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/S0959-8049(11)70937-6","article-title":"Evaluation of hand\u2212foot syndrome as a potential biomarker of sunitinib efficacy in patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor","volume":"47","author":"Puzanov","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0120","doi-asserted-by":"crossref","unstructured":"Michaelson MD, Cohen DP, Li S, et al. Hand\u2013foot syndrome as a potential biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Genitourinary Cancers Symposium 2011 [Abstract 320].","DOI":"10.1200\/jco.2011.29.7_suppl.320"},{"key":"10.1016\/j.ctrv.2014.09.001_b0125","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.bjc.6605346","article-title":"Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer","volume":"101","author":"Novello","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0130","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3109\/07357901003631080","article-title":"Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice","volume":"28","author":"Schmidinger","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2014.09.001_b0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2014.09.001_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.4008","article-title":"A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma","volume":"30","author":"Ren","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0150","unstructured":"National Comprehensive Cancer Network Guidelines Version 2. Prevention and Treatment of Cancer-Related Infections; 2011 [accessed August 21, 2012]."},{"key":"10.1016\/j.ctrv.2014.09.001_b0155","first-page":"S135","article-title":"Asthenia and fatigue as predictors of sunitinib efficacy in gastrointestinal stromal tumor","volume":"47","author":"Davis","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2010-0263","article-title":"Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities","volume":"16","author":"Kollmannsberger","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2014.09.001_b0165","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00345-010-0565-z","article-title":"Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach","volume":"28","author":"Gr\u00fcnwald","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0170","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1548-5315(11)70751-3","article-title":"Managing the side effects of sorafenib and sunitinib","volume":"3","author":"Wood","year":"2006","journal-title":"Commun Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0175","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","article-title":"A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma","volume":"50","author":"Najjar","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0180","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ctrv.2010.01.003","article-title":"Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma","volume":"36","author":"Schmidinger","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2014.09.001_b0185","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(03)12805-X","article-title":"Tyrosine kinase inhibition and grey hair","volume":"361","author":"Robert","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2014.09.001_b0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0195","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0200","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0205","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3747\/co.19.972","article-title":"Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents","volume":"19","author":"Larochelle","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0210","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0215","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"Suppl. 9","key":"10.1016\/j.ctrv.2014.09.001_b0220","article-title":"Comparative assessment of sunitinib-associated adverse events (AEs) as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC)","volume":"23","author":"Donskov","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.09.001_b0225","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S0959-8049(11)70781-X","article-title":"Neutropenia as a biomarker of sunitinib efficacy in patients with gastrointestinal stromal tumor","volume":"47","author":"Donskov","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.001_b0230","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(11)70266-2","article-title":"Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study","volume":"12","author":"Garcia-Donas","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:19:34Z","timestamp":1759655974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0305737214001480"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.09.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}